Placebo-controlled, double-blinded six-month phase 2 trial of ACH-0144471 in patients with low C3 levels due to C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs ACH 4471 (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
- 02 Nov 2017 According to Achillion media release, company plans to initiate the trial in first half of 2018.
- 18 Sep 2017 New trial record
- 11 Sep 2017 According to an Achillion Pharmaceuticals media release, patient dosing is expected in the second half of 2017.